Drug Database
AC

acrivastine + pseudoephedrine (Duact)

✓ Approved

UCB · HRH1 · Small Molecule

What is acrivastine + pseudoephedrine?

acrivastine + pseudoephedrine is a small molecule developed by UCB. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesDuact
CompanyUCB
Drug ClassSmall Molecule
Molecular TargetHRH1
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

acrivastine + pseudoephedrine acts on 1 molecular target:

HRH1histamine receptor H1 (HH1R, H1R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

acrivastine + pseudoephedrine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersSeasonal allergy✓ Approved

Related Research Articles

PubMedPhytomedicine : international journal of phytotherapy and phytopharmacology2026-05-11

Mahuang Fuzi Xixin decoction attenuates allergic rhinitis by suppressing MHC-II-mediated antigen presentation in ovalbumin induced murine model.

Wei Xiaohan X, Ding Mengze M, Tan Xiaomei X

Allergic rhinitis (AR) is a chronic condition that impairs daily life and imposes economic burdens. Mahuang Fuzi Xixin Decoction (MFXD) is a commonly employed herbal formula in China for treating AR, owing to its established clinical efficacy. However, investigations into its underlying mechanisms remain limited. To evaluate the therapeutic effects of MFXD in a mouse model of AR and to investigate its influence on antigen presentation, thereby elucidating potential mechanisms of action. An ovalbumin (OVA)-induced murine AR model was established to assess the efficacy of MFXD. Subsequently, data-independent acquisition (DIA) proteomics characterized differentially expressed proteins (DEPs) in the nasal mucosa following MFXD treatment, followed by pathway enrichment analysis. Guided by the proteomic findings, we examined the regulatory effects of MFXD on antigen presentation molecules in AR mice. Finally, human nasal epithelial cells (HNEpCs), dendritic cells (DC2.4), and Naïve CD4+ T cells isolated from OT-II mice were used to confirm the inhibitory effect of MFXD on the antigen presentation pathway. Additionally, chemical characterization of MFXD was performed. MFXD alleviated AR symptoms, mitigated histopathological alterations, and regulated plasma histamine and IgE levels, as well as IL-4, IL-13, and IFN-γ levels in the nasal lavage fluid (NLF) in AR mice. MFXD significantly reduced the number of nasal DEPs between AR and control groups, with the antigen processing and presentation pathway being the most prominently enriched. MFXD modulated splenic histopathology and spleen index, and decreased major histocompatibility complex class II (MHC-II) expression in both the nasal mucosa and spleen of AR mice. In vitro, MFXD diminished the antigen phagocytic capacity of lipopolysaccharide (LPS)-stimulated DC2.4 cells and lowered MHC-II and CD86 expression on both HNEpCs and DC2.4 cells; It also suppressed DC2.4-induced proliferation and differentiation of naive OT-II CD4+ T cells. MFXD also downregulated CD74, cathepsin S (CTSS), and MHC-II; this effect was partially reversed by the CD74 agonist MIF and by CD74 overexpression. This study explores one potential therapeutic mechanism of MFXD in AR. The findings suggests that MFXD may exert its therapeutic effect against AR by suppressing CD74/CTSS/MHC-II axis, thereby inhibiting antigen presentation. This work provides mechanistic insights that could inform the clinical use of MFXD and highlights potential targets for future AR drug development. Ephedrine, Pseudoephedrine, Methylephedrine, Benzoylmesaconine, Benzoylhypacoitine, Benzoylaconine, Asarone.

PubMedBiomolecules & therapeutics2026-04-30

Pseudoephedrine Improves Chronic Obstructive Pulmonary Disease by Regulating Airway Senescence and Mitochondrial Function through PI3K/AKT/mTOR Axis.

Wu Lijuan L, Chen Fenqiao F, Zhang He H, Xu Wenzhong W et al.

Ephedra can improve chronic obstructive pulmonary disease (COPD). Pseudoephedrine (PSE) is a main active ingredients of ephedra. It has anti-inflammatory pharmacological properties. Its effect on COPD and its possible mechanism have not been elucidated. The COPD rat model was constructed by systemic cigarette smoke exposure combined with lipopolysaccharide (LPS) tracheal instillation. BEAS-2B cells were treated using cigarette smoke extract; PSE was administered for treatment. The senescence level of rat lung tissue and bronchial epithelial cells was evaluated through staining, immunofluorescence and western blot. The mitochondrial damage of rats and BEAS-2B cells was detected by transmission electron microscopy, JC-1 probe, MitoSOX Red probe and kits. In addition, the lung function indexes of rats were detected by animal lung function analysis system. Hematoxylin and eosin (HE) staining analyzed the pathological damage. Enzyme-linked immunosorbent assay (ELISA), kit and immunohistochemistry were used to evaluate inflammation and oxidative stress. Western blot detected phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) axis protein. PSE significantly reduced senescent cells, apoptosis rate and P21 level in rat lung tissue and BEAS-2B cells, significantly increased the levels of zonula occludens-1 (ZO-1)and adenosine triphosphate (ATP), restored mitochondrial structure, and visible mitochondrial cristae. It also inhibited reactive oxygen species (ROS) levels and mitochondrial excessive fission. PSE also significantly improved lung function in rats, increased mean alveolar number (MAN), reduced pro-inflammatory factors, and increased superoxide dismutase (SOD) levels. PSE markedly suppressed p-p85, p-AKT and p-mTOR protein expressions. In addition, the PI3K/AKT agonist 740Y-P weakened the effect of PSE on improving COPD. PSE inhibited PI3K/AKT/mTOR axis, improved lung tissue senescence, mitochondrial dysfunction and pathological damage, and reduced airway inflammation and oxidative stress damage, thereby alleviating COPD.

PubMedJournal of pharmaceutical and biomedical analysis2026-04-17

A novel pharmacokinetics-pharmacodynamics strategy for effective components exploration combined with metabolomics and proteomics: Application to Xingbei Zhike granule.

Gao Xia X, Yin MingKe M, Liu Jing J, Feng Jian J et al.

Traditional Chinese medicine (TCM) is characterized by its complex and diverse components, difficult to identify the effective components. In this study, a pharmacokinetics (PK)-pharmacodynamics (PD) strategy, integrating chemical component profile, PK, metabolomics, and proteomics, was developed to explore the effective components of Xingbei Zhike granule (XBZKG) in treating post-infection cough (PIC). The quality consistency of XBZKG was confirmed by evaluating 78 components across 20 batches. And its good curative effect against PIC was verified through measurements of cough latency, cough frequency, and biochemical assays. Meanwhile, XBZKG was found to ameliorate PIC-induced metabolic disturbances, particularly in amino acid metabolism. Interestingly, the pathological state of PIC itself altered the absorption and metabolism of XBZKG in rats. Among ten components, ephedrine, pseudoephedrine, and amygdalin fitted good dose-effect models with three PD indicators, with the PIC pathological state appearing to enhance their efficacy. Spearman correlation analysis further revealed that 15 components alleviated PIC-induced amino acid imbalances, and some structurally similar components exhibited synergistic effects. Integrative proteomic and metabolomic analysis identified 28 potential pathway of XBZKG in the treatment of PIC, mainly related to inflammation. Finally, in vitro cellular assays confirmed 15 components exert good anti-inflammatory activity. This study provides a reproducible strategy for identifying effective components in TCM and offers new insights into its multi-component, multi-target, and multi-pathway therapeutic mechanisms.

PubMedAsia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists2026-04-14

Phenylephrine- and Pseudoephedrine-Associated Psychotic Relapse in Stable Schizophrenia on Long-Acting Injectables: A Case Series and Clinical Caution.

Liu Tsung-Lin TL, Lee Kuan-Lin KL, Lin Huang-Chi HC

PubMedInternational journal of phytoremediation2026-04-09

Lemna minor's accumulation and physiological response to common over-the-counter pharmaceuticals: paracetamol, pseudoephedrine, and their combination.

Urbaniak Magdalena M, Tomczyk Przemysław P, Kózka Bartosz B, Giebułtowicz Joanna J

Pharmaceutical contamination of aquatic environments is an emerging concern, particularly for over-the-counter drugs such as paracetamol (PA) and pseudoephedrine (PSE), which persist in surface waters due to incomplete wastewater treatment. This study investigated the bioaccumulation and physiological responses of Lemna minor exposed to PA, PSE, and their mixtures at environmentally relevant concentrations. Accumulation in fronds was quantified, and plant responses were assessed using biomass, chlorophyll content, and phenolic compounds. PSE showed strong, concentration-dependent accumulation, increasing significantly (p < 0.05) from 6.3 ± 1 µg/g d.w. at 0.001 mg/L to 219 ± 51 µg/g d.w. at 0.1 mg/L. In contrast, PA remained below detection limits at 0.01-0.1 mg/L and was detected only at 1 mg/L (12 ± 7 µg/g d.w.), suggesting limited uptake or rapid transformation. Under mixture exposure, PSE accumulation decreased by 39% at the lowest concentration but increased by 62% at the highest mixture level compared with single-compound treatments, whereas PA uptake remained largely unchanged. PA significantly stimulated biomass production, increasing fresh weight by up to 168% at 0.1 mg/L (p < 0.05), while PSE increased biomass by up to 119%. Low-dose exposures induced elevated phenolic levels, indicating activation of stress-related metabolic pathways, whereas higher PA concentrations enhanced chlorophyll a content, with the highest mixture treatment showing a 66% increase relative to control. PCA revealed a shift from photosynthetic investment toward secondary metabolism under pharmaceutical exposure. These asymmetric interactions demonstrate that mixture effects cannot be predicted from assays. Lemna minor exhibited sensitivity to pharmaceutical stress and a capacity to accumulate PSE, supporting its use as a bioindicator and phytoremediator.

PubMedOtology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology2026-04-03

Efficacy of Pseudoephedrine and Oxymetazoline in Preventing Otic Barotrauma: A Systematic Review and Meta-Analysis.

AlGhamdi Muhnnad A MA, Katib Renad Iyad RI, Bawazir Razan Osama RO, Alanazi Noura Farhan NF et al.

Otic barotrauma (aerotitis media) occurs when the middle-ear pressure fails to equalize during environmental pressure changes (eg, flying, diving, hyperbaric therapy). Oral pseudoephedrine and intranasal oxymetazoline are commonly used prophylactically, but comparative efficacy and the strength of evidence remain uncertain. We registered a protocol on PROSPERO (CRD420251089756) and conducted a PRISMA-guided systematic review of randomized controlled trials evaluating oral pseudoephedrine or intranasal oxymetazoline for the prevention of otic barotrauma in adults. RevMan 5.4 was used for meta-analysis. Relative risks (RR) with 95% CI were pooled using a fixed-effect generic inverse-variance model. Four double-blind randomized trials (n=490; conducted 1992-1998) met inclusion. Pseudoephedrine (3 trials) significantly reduced the risk of otic barotrauma versus placebo (RR: 0.55; 95% CI: 0.48-0.66; P<0.00001; I²=1%), and produced consistent reductions in ear pain (RR: 0.51), blockage (RR: 0.50), and hearing loss (RR: 0.49). Oxymetazoline (2 trials) showed a modest overall effect (RR: 0.75; 95% CI: 0.57-0.99; P=0.05) but inconsistent benefits across individual symptom subgroups and moderate heterogeneity (I²=53%). Safety profiles were acceptable in the small trials, although sample sizes were underpowered to detect rare harms. In adults, oral pseudoephedrine demonstrated a consistent and clinically meaningful reduction in otic barotrauma in older RCTs; intranasal oxymetazoline showed only modest and variable benefit. The evidence base is dated (1992 to 1998) and limited in size-contemporary, adequately powered RCTs with standardized outcome measures are needed. Clinicians may prefer pseudoephedrine for short-term prophylaxis in adults without contraindications, alongside non-pharmacologic measures.

+1655 more articles available with a free account

Sign up free to view all articles →

Ask about acrivastine + pseudoephedrine